abiraterone has been researched along with Cardiometabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burgio, SL; Caffo, O; Chiuri, VE; Conteduca, V; De Giorgi, U; Fratino, L; Galli, L; Kinspergher, S; Lolli, C; Maines, F; Maugeri, A; Menna, C; Salvi, S; Santini, D; Santoni, M; Scarpi, E; Schepisi, G | 1 |
| Caffo, O; Chiuri, VE; Conteduca, V; De Giorgi, U; Derosa, L; Fratino, L; Maines, F; Petracci, E; Santini, D; Santoni, M; Testoni, S; Veccia, A | 1 |
2 other study(ies) available for abiraterone and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Association among metabolic syndrome, inflammation, and survival in prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Follow-Up Studies; Humans; Inflammation; Male; Metabolic Syndrome; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Rate | 2018 |
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Humans; Male; Metabolic Syndrome; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Steroid 17-alpha-Hydroxylase; Survival Rate; Treatment Outcome | 2015 |